Digital Life Line, a stepdown subsidiary DISA (SGX:532) unit DiSa Digital Safety, received an approval for the clinical deployment of its Automated Visual Acuity Test device at a hospital ophthalmology clinic in Hong Kong.
Initially, the device went through a successful three-month trial deployment at a public ophthalmology clinic in Hong Kong, according to a filing with the Singapore Exchange on Wednesday.
The device is aimed at combating myopia, which affects more than 40% of school children in Hong Kong.
Shares of the company surged 100% in recent trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.